• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA >Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty.
【24h】

Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty.

机译：特立帕肽与椎体成形术与抗吸收剂联合治疗经皮椎体成形术后新发相邻椎体压缩性骨折的疗效比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Most post-vertebroplasty new-onset adjacent vertebral compression fractures (VCFs) occur within 2-3?months, and antiresorptive agents do not significantly reduce the risk of their occurrence. In opposite mechanism, teriparatide directly stimulates bone formation and improves bone strength and quality faster. The therapeutic effect of teriparatide is better than that of vertebroplasty combined with an antiresorptive treatment and is a potentially useful therapy for new-onset adjacent VCFs after vertebroplasty.Following vertebroplasty, patients are at increased risk of new-onset adjacent-level VCFs. The therapeutic effect of antiresorptive agents is too slow, and they are associated with the risk of new VCFs. Teriparatide markedly increases bone formation and strength and reduces the incidence of new-onset VCFs. This prospective cohort study compared the therapeutic effects of teriparatide with those of combined vertebroplasty and an anti-resorber for treating new-onset adjacent VCFs after vertebroplasty.Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B). Relevant clinical data of the two groups were prospectively compared.The 22 patients in group A were at higher risk of new VCFs than those in group B (22 patients); they were older and had more pre-existing fractures (p?
机译：椎体成形术后大多数新发的相邻椎体压缩性骨折（VCF）发生在2-3月内，而抗吸收剂并不能显着降低其发生的风险。在相反的机制中，特立帕肽直接刺激骨骼形成并更快地提高骨骼强度和质量。特立帕肽的治疗效果优于椎体成形术与抗吸收治疗相结合，对于椎体成形术后新发相邻的VCFs可能是有用的疗法。抗再吸收剂的治疗作用太慢，并且与新的VCF风险相关。特立帕肽显着增加了骨骼的形成和强度，并减少了新发VCF的发生。这项前瞻性队列研究比较了特立帕肽，联合椎体成形术和抗吸收剂治疗椎体成形术后新发相邻VCF的疗效.50例具有相邻VCF的患者随机分为两组：仅特立帕肽（A组）和其他椎体成形术联合抗吸收剂（B组）。前瞻性比较了两组的相关临床数据。A组的22例患者发生新VCF的风险高于B组（22例）。他们年纪大些，并且有更多的既往骨折（p <0.05）。接受特立帕肽治疗的患者新发VCF的发生率显着降低（几率= 0.21; 95％置信区间0.02-2.10）。特立帕肽介导的VCF降低为78.57％，明显优于B组。特立帕肽组在治疗6个月后，视觉模拟评分明显降低，日本骨科协会腰痛评分增加（ p≤0.05。特立帕肽治疗18个月后，腰椎BMD明显增加（21.70％对6.87％）。特立帕肽治疗椎体成形术后邻近VCF（无新椎体成形术）比重复椎体成形术联合治疗更有效与抗吸收剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号